Dr. Saab on Napabucasin (BBI-608) in Colorectal Cancer Treatment

Tanios Bekaii-Saab, MD
Published: Tuesday, Jun 20, 2017



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

A phase III study that investigated single-agent napabucasin versus placebo did not reach its primary endpoint, Bekaii-Saab explains. However, in the patients with the p-STAT3 expression, it was found that the hazard ratio was .21, telling researchers that the mechanism of action of this drug perhaps is what's leading the clinical activity in this patient population. When this agent is combined with chemotherapy, the STAT3 expression is not as significant, he adds.

Therefore, there are other synergy levels with chemotherapy and other biomarkers that are being explored.
SELECTED
LANGUAGE


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

A phase III study that investigated single-agent napabucasin versus placebo did not reach its primary endpoint, Bekaii-Saab explains. However, in the patients with the p-STAT3 expression, it was found that the hazard ratio was .21, telling researchers that the mechanism of action of this drug perhaps is what's leading the clinical activity in this patient population. When this agent is combined with chemotherapy, the STAT3 expression is not as significant, he adds.

Therefore, there are other synergy levels with chemotherapy and other biomarkers that are being explored.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x